Why US Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector

Private equity (PE) participation in US healthcare has accelerated over the past decade, drawing scrutiny from federal and state regulators as well as politicians. While the Biden-era FTC and DOJ framed PE-backed ‘roll-ups’ as threats to competition and patient welfare, early actions under the second Trump administration signalled a return to a less-hostile view of private equity. In recent years, at least 15 states passed ‘mini-HSR’ statutes to facilitate review of smaller deals, particularly in healthcare. Recent headline cases – US Anesthesia Partners/Welsh Carson, JAB-Ethos Veterinary and Surmodics/GTCR – illustrate the agencies’ willingness to challenge acquisitions involving private equity firms and attempts to craft forward-looking relief that may affect future deal making.

Read the full article: Why US Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector //

Source: https://globalcompetitionreview.com/review/the-antitrust-review-of-the-americas/2026/article/why-us-regulators-are-cracking-down-private-equity-investments-in-the-healthcare-sector

Scroll to Top